SCHEDULE: Opaleye Management Discloses 9.48% Stake in Karyopharm

Opaleye Management Inc., Opaleye, L.P., and James Silverman have jointly reported a beneficial ownership of 9.48% in Karyopharm Therapeutics Inc. common stock.

Summary

• Opaleye Management Inc., Opaleye, L.P., and James Silverman (collectively, the "Filers") have filed a Schedule 13G.
• The filing reports beneficial ownership of 1,569,002 shares of Karyopharm Therapeutics Inc. common stock.
• This represents 9.48% of the issuer's outstanding common stock.
• The ownership includes 619,089 shares issuable upon the exercise of immediately exercisable warrants.
• The percentage is calculated based on Karyopharm Therapeutics Inc.'s expected 15,926,939 shares outstanding following consummation of transactions described in an October 8, 2025 Form 8-K.
• The Filers certify that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a substantial passive investment by Opaleye Management Inc. in Karyopharm Therapeutics Inc., suggesting investor confidence in the company's long-term value.

Positives

• A significant institutional investor, Opaleye Management Inc., has taken a substantial 9.48% stake, indicating potential confidence in Karyopharm Therapeutics Inc.'s long-term prospects.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests a long-term holding strategy rather than an activist intent.

Negatives

• NA

Risks

• The filing does not detail specific risks related to Karyopharm Therapeutics Inc.'s operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

The filing is a passive ownership disclosure and does not contain forward-looking statements or guidance from Karyopharm Therapeutics Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates a significant passive investment by an institutional fund, Opaleye Management Inc., which specializes in healthcare and life sciences, in Karyopharm Therapeutics Inc. Such substantial investments are common in the biotech sector, where specialized funds often take positions in companies with promising drug pipelines or technologies, signaling confidence in the sector's growth potential.

Comparison to Industry Standards

• A 9.48% stake is a substantial position for an institutional investor, often signaling strong conviction in the company's long-term prospects, particularly in the biotech sector where early-stage investments can yield significant returns.
• Compared to typical institutional holdings, this percentage places Opaleye as a significant shareholder, potentially among the top institutional holders, which can be viewed positively by other investors.
• The passive nature of the filing (Schedule 13G vs. 13D) indicates that Opaleye is not seeking to influence management or control the company, aligning with common passive investment strategies for funds focused on sector-specific growth.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Existing shareholders may view the significant stake by Opaleye Management Inc. as a positive signal of institutional confidence, potentially leading to increased investor interest.
• Management: Management may see this as validation of their strategy, though the passive nature of the filing means no immediate pressure for strategic changes.

Next Steps

• NA

Key Dates

Recommendation

The disclosure of a significant 9.48% passive stake by Opaleye Management Inc., a specialized healthcare investor, suggests institutional confidence in Karyopharm Therapeutics Inc. While this is a positive indicator, the filing itself does not provide fundamental financial or operational updates to warrant a stronger 'buy' recommendation. It primarily signals that a notable investor sees value, which supports holding the stock for existing investors.

Keywords

Karyopharm Therapeutics, Opaleye Management, Schedule 13G, beneficial ownership, common stock, institutional investor, biotech, pharmaceutical, investment